Search - tctmd.com

Displaying 261 - 280 of 432

Sort: Relevancy | Date

News Daily News

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

Caitlin E. Cox

September 29, 2017

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

Shelley Wood

September 28, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

Presentation

Association of PVR With 1-Year Outcomes After TAVR With Sapien 3 Valve

September 27, 2017

News Daily News

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

Yael L. Maxwell

August 24, 2017

Manuscript

Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort

August 08, 2017

News Daily News

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

Michael O'Riordan

July 17, 2017

News Daily News

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

Michael O'Riordan

July 10, 2017

News Daily News

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Michael O'Riordan

June 26, 2017

News Conference News TVT 2017

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Shelley Wood

June 19, 2017

News Conference News TVT 2017

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Michael O'Riordan

June 17, 2017

News Conference News TVT 2017

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Shelley Wood

June 16, 2017

News Conference News TVT 2017

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

Shelley Wood

June 12, 2017

News Daily News

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Michael O'Riordan

June 06, 2017

News Daily News

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Michael O'Riordan

June 06, 2017

Presentation

Outcomes With Boston Scientific Lotus Valve and Edwards Lifesciences Sapien 3

June 06, 2017

News Conference News EuroPCR 2017

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

Michael O'Riordan

May 26, 2017

News Conference News EuroPCR 2017

More Early Stroke With SAVR Than TAVR in SURTAVI

Shelley Wood

May 18, 2017

News Conference News EuroPCR 2017

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

Michael O'Riordan

May 17, 2017

News Conference News EuroPCR 2017

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

Shelley Wood

May 17, 2017

Advertisement

Hemodynamics of First-Gen Sapien Valve Hold Up Well Over the Years: PARTNER Analysis

CT Scans Before and After TAVR Show Tricuspid, Bicuspid Valves Are Reassuringly Similar

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Association of PVR With 1-Year Outcomes After TAVR With Sapien 3 Valve

After Failed Mitral Valve Surgery, Transcatheter Valve-in-Valve or Valve-in-Ring Shows Promise in High-Risk Patients

Standardized Minimalistic Transfemoral Transcatheter Aortic Valve Replacement (TAVR) Using the SAPIEN 3 Device: Stepwise Description, Feasibility, and Safety from a Large Consecutive Single-Center Single-Operator Cohort

TAVR Equivalent to Surgery in Real-World Practice, New Analysis Shows

FDA Expands CoreValve Indication to Include Intermediate-Risk Patients

TAVR Use Triples in France, With Docs Treating Lower-Risk Patients

Valve Leaflet Thrombosis: Treat It or Leave It Be?

Lagging Behind: Guidelines Can’t Keep Up With Growing TAVR Evidence Base

Reacting to REPRISE III: Enthusiasm, Explanations, and Caveats for the Lotus Pivotal TAVR Trial

Q&A: Transcatheter Valve Innovation Past, Present, and Future as TVT Turns 10

FDA Expands Sapien 3 Indication to Aortic, Mitral Valve-in-Valve Replacement

Lotus Matches Sapien in Single-Center Study, but Pacemaker Use Poses Questions

Outcomes With Boston Scientific Lotus Valve and Edwards Lifesciences Sapien 3

Embolic Protection During TAVR Reduces Volume of Cerebral Lesions, but Clinical Benefit Not Evident: Meta-analysis

More Early Stroke With SAVR Than TAVR in SURTAVI

Bicuspid AS Patients with Calcification Fare Worse After TAVR, But Device Type Matters

If They Survive First Month, Mitral Annular Calcification Patients Treated With Transcatheter Valves Do Well at 1 Year

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content